Biktarvy Gilead Sciences | Bictegravir / Emtricitabine / TAF | INSTI + NRTI/NtRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Celsentri ViiV Healthcare | Maraviroc | Entry Inhibitor | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Descovy Gilead Sciences | Emtricitabine / TAF | NRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Dovato ViiV Healthcare | Dolutegravir / Lamivudine | INSTI + NRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Edurant Janssen | Rilpivirine | NNRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Local Manufacturers | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully reimbursed by SGK (local generic alternatives are widely available and commonly prescribed). [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Genvoya Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / TAF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Intelence Janssen | Etravirine | NNRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Isentress Merck | Raltegravir | INSTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Kaletra AbbVie | Lopinavir / Ritonavir | PI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Odefsey Gilead Sciences | Rilpivirine / Emtricitabine / TAF | NNRTI + NRTI/NtRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Pifeltro Merck | Doravirine | NNRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Prezista Janssen | Darunavir | PI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Symtuza Janssen | Darunavir / Cobicistat / Emtricitabine / TAF | PI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Tivicay ViiV Healthcare | Dolutegravir | INSTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Triumeq ViiV Healthcare | Dolutegravir / Abacavir / Lamivudine | INSTI + NRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Truvada Gilead Sciences | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Vocabria ViiV Healthcare | Cabotegravir | INSTI | Reimbursed | Fully reimbursed by the Social Security Institution (SGK) with an infectious disease specialist report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Delstrigo Merck | Doravirine / Lamivudine / Tenofovir DF | NNRTI + NRTI/NtRTI | Available, not reimbursed | Approved by the Ministry of Health but currently not covered under the SGK reimbursement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Rukobia ViiV Healthcare | Fostemsavir | Attachment Inhibitor | Available, not reimbursed | Approved by the Ministry of Health but currently not covered under the SGK reimbursement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Sunlenca Gilead Sciences | Lenacapavir | Capsid Inhibitor | Available, not reimbursed | Approved by the Ministry of Health but currently not covered under the SGK reimbursement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics) | Tenofovir DF / Lamivudine / Dolutegravir | INSTI + NRTI/NtRTI | Not available | Not registered in the pharmaceutical market or not included in the public procurement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics) | Tenofovir DF / Lamivudine / Efavirenz | NNRTI + NRTI/NtRTI | Not available | Not registered in the pharmaceutical market or not included in the public procurement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Juluca ViiV Healthcare | Dolutegravir / Rilpivirine | INSTI + NNRTI | Not available | Not registered in the pharmaceutical market or not included in the public procurement list. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Rekambys Janssen | Rilpivirine | Long-Acting NNRTI | Not available | Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Turkey record for the complete Vocabria / Rekambys regimen is classified as 'Not Available', so this required rilpivirine component uses the same access and reimbursement status. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys] | 14/09/2026 |
Vocabria / Rekambys ViiV Healthcare / Janssen | Cabotegravir / Rilpivirine | Long-Acting ART | Not available | It does not have a licence from the Ministry of Health. It can only be imported via Overseas Medicines Procurement Centres, accompanied by a prescription and a medical report. [Source: SGK SUT (Health Implementation Communiqué)] | 14/09/2026 |
Apretude ViiV Healthcare | Cabotegravir (PrEP) | INSTI (Long-Acting PrEP) | Under review | Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis. The EU/EEA-wide marketing authorisation of 19 September 2023 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude] | 14/09/2026 |
Emtriva Gilead Sciences | Emtricitabine | NRTI | Under review | Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva] | 14/09/2026 |
Epivir ViiV Healthcare | Lamivudine | NRTI | Under review | Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir] | 14/09/2026 |
Eviplera Gilead Sciences | Rilpivirine / Emtricitabine / Tenofovir DF | NNRTI + NRTI/NtRTI | Under review | A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera] | 14/09/2026 |
Kivexa ViiV Healthcare | Abacavir / Lamivudine | NRTI | Under review | A fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa] | 14/09/2026 |
Norvir AbbVie | Ritonavir | PI + pharmacokinetic enhancer | Under review | Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir] | 14/09/2026 |
Retrovir ViiV Healthcare | Zidovudine | NRTI | Under review | Zidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir] | 14/09/2026 |
Rezolsta Janssen | Darunavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta] | 14/09/2026 |
Stribild Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Under review | A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild] | 14/09/2026 |
Viread Gilead Sciences | Tenofovir DF | NtRTI | Under review | Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread] | 14/09/2026 |
Yeytuo Gilead Sciences | Lenacapavir (PrEP) | Capsid Inhibitor (Long-Acting PrEP) | Under review | Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The EU/EEA-wide marketing authorisation of 26 August 2025 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. An identical product, Lenacapavir Gilead, received a positive EMA opinion under the EU-M4all procedure for use outside the EU. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo] | 14/09/2026 |
Ziagen ViiV Healthcare | Abacavir | NRTI | Under review | Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Turkey. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen] | 14/09/2026 |